| Pulmonary arterial hypertension

Revatio vs Tracleer

Side-by-side clinical, coverage, and cost comparison for pulmonary arterial hypertension.

Deep comparison between: Revatio vs Tracleer with Prescriber.AI

AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.

Safety signalsTracleer has a higher rate of injection site reactions vs Revatio based on FDA-approved prescribing information

Coverage gaps3 major payers require step therapy for Tracleer but not Revatio, including UnitedHealthcare

Category

Revatio

Tracleer

At A Glance

RouteOral or IV bolus

FrequencyThree times a day

ClassPDE-5 inhibitor

RouteOral

FrequencyTwice daily

ClassEndothelin receptor antagonist

Indications

Pulmonary arterial hypertension

Pulmonary arterial hypertension

Dosing

Pulmonary arterial hypertension Adults: 20 mg orally three times a day (may titrate to 80 mg three times a day) or 10 mg IV bolus three times a day; pediatric patients <=20 kg: 10 mg orally three times a day; 20-45 kg: 20 mg three times a day; >45 kg: 20 mg three times a day (may titrate to 40 mg three times a day).

Pulmonary arterial hypertension Adults and patients >12 years and >40 kg: 62.5 mg orally twice daily for 4 weeks, then 125 mg twice daily; patients >12 years and <=40 kg: 62.5 mg twice daily; pediatric patients <=12 years: weight-based dosing ranging from 16 mg to 64 mg twice daily.

Contraindications

Concomitant use of organic nitrates in any form, either regularly or intermittently, due to risk of hypotension
Concomitant use of riociguat, a guanylate cyclase stimulator
Known hypersensitivity to sildenafil or any component of the tablet, injection, or oral suspension

Pregnancy
Concomitant use with cyclosporine A
Concomitant use with glyburide
Hypersensitivity to bosentan or any component of the product

Drug Interactions

1152View drug interactions

1139View drug interactions

Adverse Reactions

Most common (>=10%) Headache, flushing, pain in limb, myalgia, back pain, dyspepsia, diarrhea

Serious Hypotension, vision loss, hearing loss, priapism, vaso-occlusive crisis

Postmarketing Myocardial infarction, sudden cardiac death, ventricular arrhythmia, cerebrovascular hemorrhage, transient ischemic attack, hypertension, pulmonary hemorrhage, seizure, NAION

Most common (>=3%) Respiratory tract infection, headache, edema, chest pain, syncope, flushing, hypotension, sinusitis, arthralgia, abnormal serum aminotransferases, palpitations, anemia

Serious Hepatotoxicity, embryo-fetal toxicity, fluid retention, decreased sperm counts, decreases in hemoglobin and hematocrit

Postmarketing Angioedema, unexplained hepatic cirrhosis, liver failure, hypersensitivity/DRESS/anaphylaxis, thrombocytopenia, rash, jaundice, anemia requiring transfusion, neutropenia, leukopenia, nasal congestion, autoimmune hepatitis

Pharmacology

Sildenafil is a selective inhibitor of cGMP-specific PDE-5 in pulmonary vascular smooth muscle; by blocking PDE-5-mediated cGMP degradation, it elevates cGMP levels resulting in relaxation and vasodilation of the pulmonary vascular bed in patients with PAH.

Bosentan is a specific and competitive antagonist at endothelin receptor types ETA and ETB, blocking the vasoconstrictive and proliferative effects of endothelin-1, a neurohormone elevated in plasma and lung tissue of patients with PAH.

View Full FDA Information

View full FDA information

Enter your patient's insuranceCheck specific coverage details for your patient.

Most Common Insurance

Anthem BCBS

Revatio